The Impact of COPD on In-Hospital Outcomes in Patients with Takotsubo Cardiomyopathy
Overview
Affiliations
Purpose: Chronic obstructive pulmonary disease (COPD) is a known comorbidity of takotsubo cardiomyopathy (TCM), and COPD exacerbation is a potential triggering factor of TCM. The association between COPD and in-hospital outcomes and complications among TCM patients is not well established. We sought to assess the effect of COPD on hospitalized patients with a primary diagnosis of TCM.
Methods: We conducted a retrospective cohort study in patients with a primary diagnosis of TCM with or without COPD using the latest National Inpatient Sample from 2016-2017. We identified 3139 patients admitted with a primary diagnosis of TCM by the ICD-10-CM coding system; 684 of those patients also had a diagnosis of COPD. We performed propensity score matching in a 1:2 ratio (n=678 patients, matched COPD group; n=1070, matched non-COPD group) and compared in-hospital outcomes and complications between TCM patients with and without a COPD diagnosis.
Results: Before matching, the COPD group had worse outcomes compared with the non-COPD group in inpatient death (2.9% vs 1.3%, p=0.006), length of stay (LOS) (4.02±2.99 days vs 3.27±3.39 days, p<0.001), hospitalization charges ($55,242.68±47,637.40 vs $48,316.97±47,939.84, p=0.001), and acute respiratory failure (ARF) (22.5% vs 7.7%, p<0.001), respectively. After propensity score matching, the matched COPD group, compared with the matched non-COPD group, had a higher inpatient mortality rate (2.9% vs1.0%, p=0.005), longer LOS (4.02±3.00 days vs 3.40±3.54 days, p<0.001), higher hospitalization charges ($55,409.23±47,809.13 vs $46,469.60±42,209.10, p<0.001), and a higher incidence of ARF (22.6% vs 8.2%, p<0.001) and cardiogenic shock (5.6% vs 3.3%, p=0.024), respectively.
Conclusion: Patients with COPD who are hospitalized for TCM have higher rates of inpatient mortality, ARF, cardiogenic shock, as well as a longer LOS, and higher charges of stay than those without COPD. Prospective studies are warranted to examine the effect of early intervention or treatment of COPD on short- and long-term outcomes of TCM.
Ruan H, Yang Q, Zhao X, Tang Q, Feng Y Asia Pac J Clin Nutr. 2025; 34(1):66-75.
PMID: 39828259 PMC: 11742601. DOI: 10.6133/apjcn.202502_34(1).0006.
Tantillo S, Guarnera M, Benvenuti F, Ottaviani I, Cilloni N Cureus. 2024; 16(9):e69638.
PMID: 39429330 PMC: 11487488. DOI: 10.7759/cureus.69638.
Takotsubo Syndrome in Patients With COVID-19: A Systematic Review.
Lu X, Teng C, Cai P, Liang J, Wang Y, Abu H CJC Open. 2024; 6(6):818-825.
PMID: 39022174 PMC: 11251070. DOI: 10.1016/j.cjco.2024.03.004.
Incidence and Impact of Takotsubo Syndrome in Hospitalized Patients With COVID-19.
Li P, Shi A, Lu X, Li C, Cai P, Teng C Tex Heart Inst J. 2024; 51(1).
PMID: 38708821 PMC: 11075496. DOI: 10.14503/THIJ-23-8309.
Takotsubo syndrome and respiratory diseases: a systematic review.
Li P, Wang Y, Liang J, Zuo X, Li Q, Sherif A Eur Heart J Open. 2022; 2(2):oeac009.
PMID: 35919117 PMC: 9242042. DOI: 10.1093/ehjopen/oeac009.